


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-3.96%
+11.86%
+2.20%
+0.68%
CMPX
Compass Therapeutics
$5.79
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
CMPX Price Performance
$4.96 (+16.73%)
$4.05 (+42.96%)
$3.02 (+91.72%)
$3.22 (+79.81%)
CMPX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

CMPX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
CMPX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CMPX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
CMPX
Compass Therapeutics
5.79
-4.22%
ETR
Entergy
95.63
+0.48%
TS
Tenaris
41.54
-2.15%
QTWO
Q2 Holdings
66.90
-2.80%
LFUS
Littelfuse Comm
293.79
+4.80%
What is CMPX current stock price?
What are CMPX stock strengths?
What is CMPX Risk Level?
What is CMPX market cap and volume?
What is CMPX current Stock IQ?
Should I buy CMPX stock right now?
Is CMPX a Strong Buy right now?
What does a 'Strong Buy' rating mean for CMPX?
What does a 'Strong Sell' rating mean for CMPX?
What factors influence CMPX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-3.96%
+11.86%
+2.20%
+0.68%
CMPX
Compass Therapeutics
Current Price
$5.79
CMPX Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Recently Viewed
CMPX
Compass Therapeutics
5.79
-4.22%
ETR
Entergy
95.63
+0.48%
TS
Tenaris
41.54
-2.15%
QTWO
Q2 Holdings
66.90
-2.80%
LFUS
Littelfuse Comm
293.79
+4.80%

CMPX Price Performance
$4.96 (+16.73%)
$4.05 (+42.96%)
$3.02 (+91.72%)
$3.22 (+79.81%)
CMPX Analysts Opinion
CMPX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
CMPX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CMPX Street Sentiment is extremely bullish and have positive views on the near-term outlook
CMPX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
CMPX Latest Analysis
Compass Therapeutics Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Wed Jan 14, 2026
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation. Fintel reports that on January 5 2026 William Blair initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Outperform recommendation. Analyst Price Forecast Suggests 142.82% Upside
Mon Jan 5, 2026
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). BOSTON Jan. 05 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (NASDAQ:) a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases today announced it granted stock options to two new employees under the Company'.s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4)
Mon Jan 5, 2026
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). BOSTON Jan. 05 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX) a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases today announced it granted stock options to two new employees under the Companys 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mon Jan 5, 2026
Compass Therapeutics Appoints Cynthia Sirard As CMO. Shares Surge In Pre-market . (RTTNews) - Compass Therapeutics Inc. (CMPX) a clinical-stage oncology-focused biopharmaceutical company on Monday announced that it has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer effective as of January 1 2026.
Mon Jan 5, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CMPX Stock trends
CMPX Stock performance
CMPX Stock analysis
CMPX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.